Top Abstract Purchase Related
Home
>
Node
>
Subnode

A potent, cost-effective RNase inhibitor

Murphy, N.R.; Leinbach, S.S.; Hellwig, R.J.

Biotechniques 18(6): 1068-1073

1995

ISSN/ISBN: 0736-6205
PMID: 7546711
Document Number: 441535
The performance characteristics of a potent new RNase inhibitor have been evaluated, as have applications for its use in molecular biology. PRIME Inhibitor is a protein, not related to the commonly available human placental RNase inhibitors (HPRI). It has a high specific activity, enhanced temperature stability, broad reaction pH range and significantly greater cost-effectiveness than commercial HPRI. PRIME Inhibitor is suitable for use in in vitro transcription, in vitro translation, first- and second-strand cDNA synthesis, preparation of RNA and mRNA, and reverse transcription-polymerase chain reaction.

Document emailed within 1 workday
Secure & encrypted payments

Parfenova, M.S.; Maksimovich, M.B.; Bukovetskiĭ, S.I.; Tishechkina, V.A.; Lisovaia, S.P. 1976: Inhibitor participation in the regulation of serum RNAse activity in the formation of immunity against influenza Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 6: 37-41
Brugge, W.R.; Rosenfeld, M.S. 1987: Impairment of starch absorption by a potent amylase inhibitor American Journal of Gastroenterology 82(8): 718-722
Browning, E.T.; Groppi, V.E.; Kon, C. 1974: Papaverine, a potent inhibitor of respiration in C-6 astrocytoma cells Molecular Pharmacology 10(1): 175-181
Wen, X.; Wang, J.S.; Backman, J.T.; Kivistö, K.T.; Neuvonen, P.J. 2001: Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9 Drug Metabolism and Disposition: the Biological Fate of Chemicals 29(11): 1359-1361
Stanĕk, R.; Cinátl, J.; Matousek, J. 1978: The effect of bovine pancreatic ribonuclease (A RNase) and bull seminal ribonuclease (AS RNase) on human lymphocytes undergoing blastic transformation Folia Biologica 24(2): 111-117
Lin, J.H.; Chen, I.W.; Vastag, K.J.; Ostovic, D. 1995: pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs Drug Metabolism and Disposition: the Biological Fate of Chemicals 23(7): 730-735
Frye, S.V.; Bramson, H.N.; Hermann, D.J.; Lee, F.W.; Sinhababu, A.K.; Tian, G. 1998: Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase Pharmaceutical Biotechnology 11: 393-422
Veres, Z.; Szinai, I.; Szabolcs, A.; Ujszászy, K.; Dénes, G. 1987: Biological activity of the potent uridine phosphorylase inhibitor 5-ethyl-2,2'-anhydrouridine Drugs under Experimental and Clinical Research 13(10): 615-621
Hara, H.; Tamao, Y.; Kikumoto, R.; Funahara, Y.; Hijikata, A.; Okamoto, S. 1980: Effect of a potent thrombin inhibitor, No. 407, on platelet function in vitro and in vivo Kobe Journal of Medical Sciences 26(1): 47-60
Skurský, L.; Khan, A.N.; Saleem, M.N.; al-Tamer, Y.Y. 1992: A new potent inhibitor of horse liver alcohol dehydrogenase: p-methylbenzyl hydroperoxide Biochemistry International 26(5): 899-904
Sabała, P.; Czarny, M.; Woronczak, J.P.; Barańska, J. 1993: Thapsigargin: potent inhibitor of Ca2+ transport ATP-ases of endoplasmic and sarcoplasmic reticulum Acta Biochimica Polonica 40(3): 309-319
Miller, D.W.; Koch, S.B.; Yentzer, B.A.; Clark, A.R.; O'Neill, J.R.; Fountain, J.; Weber, T.M.; Fleischer, A.B. 2011: An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial Journal of Drugs in Dermatology: Jdd 10(5): 531-537
Medina, J.H.; Novas, M.L.; De Robertis, E.; Pena, C.; Paladini, A.C. 1986: Identification of a potent endogenous benzodiazepine binding inhibitor from bovine cerebral cortex Advances in Biochemical Psychopharmacology 42: 47-56
Chen, C.Y.; Tan, L. 1999: Chemical process evolution of efavirenz, a potent non-nucleosidal HIV reverse transcriptase inhibitor Enantiomer 4(6): 599-608
Lipkin, G.; Knecht, M.E.; Rosenberg, M. 1978: A potent inhibitor of normal and transformed cell growth derived from contact-inhibited cells Cancer Research 38(3): 635-643
Hall, E.D.; Braughler, J.M.; Yonkers, P.A.; Smith, S.L.; Linseman, K.L.; Means, E.D.; Scherch, H.M.; Von Voigtlander, P.F.; Lahti, R.A.; Jacobsen, E.J. 1991: U-78517F: a potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischemia Journal of Pharmacology and Experimental Therapeutics 258(2): 688-694
Trapani, A.J.; De Lombaert, S.; Erion, M.D.; Ghai, R.D.; Peppard, J.V.; Lappe, R.W.; Worcel, M. 1993: The pharmacology of CGS 25462: a potent, orally bioavailable, long-acting inhibitor of neutral endopeptidase 24.11 Journal of Hypertension. Suppl: Official Journal of the International Society of Hypertension 11(5): S220-S221
Jones, T.R.; Charette, L.; Garcia, M.L.; Kaczorowski, G.J. 1990: Selective inhibition of relaxation of guinea-pig trachea by charybdotoxin, a potent Ca(++)-activated K+ channel inhibitor Journal of Pharmacology and Experimental Therapeutics 255(2): 697-706
Valenti, W.M. 1999: HIV care is effective and cost-effective Aids Reader 9(8): 530
Zhang, Y.; Zheng, Y. 2016: Effects and mechanisms of potent caspase-1 inhibitor VX765 treatment on collagen-induced arthritis in mice Clinical and Experimental Rheumatology 34(1): 111-118